Lynparza 150 — Olaparib 150 mg (112 Tablets)

Lynparza is used for the treatment and maintenance therapy of adult patients in the following conditions:

• 🔹 Ovarian Cancer: Maintenance treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (with or without BRCA mutations).
• 🔹 Breast Cancer: HER2-negative metastatic breast cancer with germline BRCA mutations.
• 🔹 Pancreatic Cancer: Maintenance treatment of metastatic pancreatic adenocarcinoma with BRCA mutations.
• 🔹 Prostate Cancer: Metastatic castration-resistant prostate cancer with mutations in DNA repair genes.

Sales Form: 1 pack contains 112 tablets of 150 mg (2 bottles/blisters of 56 tablets each).

⚠️ INSTRUCTIONS FOR USE:

• Dosage Regimen: The standard dosage is 300 mg (two 150 mg tablets) twice daily. Total daily dose is 600 mg.
• Method: Tablets should be swallowed whole; do not chew, crush, or dissolve. They can be taken with or without food.
• Duration: Treatment continues until disease progression or unacceptable toxicity occurs.
• Important: Do not substitute Lynparza tablets with Lynparza capsules (50 mg) on a mg-to-mg basis without consulting a doctor, as they differ in bioavailability.
• Storage: Store in the original packaging at a temperature not exceeding 30°C.

• ⛔ Hypersensitivity: Hypersensitivity to olaparib or any components of the drug.
• ⛔ Pregnancy and Lactation: The drug has teratogenic effects. Strictly contraindicated for pregnant women. Breastfeeding must be discontinued during therapy and for one month after completion.
• ⛔ Severe Impairments: Severe renal impairment (dose adjustment is required for moderate cases).
• ⛔ Age: Not recommended for children and adolescents under 18 years of age.

The most common side effects observed with Lynparza:

• 🩸 Hematology: Anemia (low hemoglobin), neutropenia, leukopenia. Regular monitoring of complete blood count is required.
• 🤢 GI Tract: Nausea, vomiting, diarrhea, changes in taste (dysgeusia), decreased appetite.
• 🤕 General: Fatigue (asthenia), dizziness, headache.
• 🫁 Respiratory System: Shortness of breath, cough (rarely — pneumonitis).
• ⚠️ Important: If severe shortness of breath, fever, or signs of infection develop, contact your oncologist immediately. In rare cases, there is a risk of developing myelodysplastic syndrome (MDS).